Cargando…
KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
PURPOSE: Limited data are available about the influence of KIT and PDGFRA mutations on overall survival (OS) of patients with gastrointestinal stromal tumor (GIST) treated with adjuvant imatinib. PATIENTS AND METHODS: The Scandinavian Sarcoma Group XVIII/AIO multicenter trial accrued 400 patients wi...
Autores principales: | Joensuu, Heikki, Wardelmann, Eva, Eriksson, Mikael, Reichardt, Annette, Hall, Kirsten Sundby, Schütte, Jochen, Cameron, Silke, Hohenberger, Peter, Sihto, Harri, Jost, Philipp J., Lindner, Lars H., Bauer, Sebastian, Nilsson, Bengt, Kallio, Raija, Pesonen, Tommi, Reichardt, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472091/ https://www.ncbi.nlm.nih.gov/pubmed/37014660 http://dx.doi.org/10.1158/1078-0432.CCR-22-3980 |
Ejemplares similares
-
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study
por: Bauer, Sebastian, et al.
Publicado: (2021) -
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib
por: Joensuu, Heikki, et al.
Publicado: (2014) -
KIT and PDGFRA Variants and the Survival of Patients with Gastrointestinal Stromal Tumor Treated with Adjuvant Imatinib
por: Joensuu, Heikki
Publicado: (2023) -
Fibrinogen‐like protein 2 in gastrointestinal stromal tumour
por: Pulkka, Olli‐Pekka, et al.
Publicado: (2022) -
SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour
por: Pulkka, Olli-Pekka, et al.
Publicado: (2017)